Back to Search
Start Over
Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
- Source :
- Vaccines; Volume 9; Issue 9; Pages: 947, Vaccines, Vaccines, Vol 9, Iss 947, p 947 (2021)
- Publication Year :
- 2021
- Publisher :
- Multidisciplinary Digital Publishing Institute, 2021.
-
Abstract
- The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators.
- Subjects :
- medicine.medical_specialty
Immunology
Article
Serology
Persistence (computer science)
SARS-CoV-2
healthcare workers
COVID-19
vaccine
mRNA vaccine
anti-S-RBD antibodies
Drug Discovery
Health care
Pandemic
Medicine
Pharmacology (medical)
Pharmacology
biology
business.industry
Public health
Virology
Vaccination
Settore MED/44
Titer
Infectious Diseases
Anti-S-RBD antibodies
Healthcare workers
MRNA vaccine
Vaccine
biology.protein
Antibody
business
Subjects
Details
- Language :
- English
- ISSN :
- 2076393X
- Database :
- OpenAIRE
- Journal :
- Vaccines; Volume 9; Issue 9; Pages: 947
- Accession number :
- edsair.doi.dedup.....0ba72b4e0db784ee98d9bfd8fdc08c63
- Full Text :
- https://doi.org/10.3390/vaccines9090947